|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Globalcancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brenton JD, Carey LA, Ahmed AA and Caldas
C: Molecular classification and molecular forecasting of breast
cancer: Ready for clinical application? J Clin Oncol. 23:7350–7360.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bombonati A and Sgroi DC: The molecular
pathology of breast cancer progression. J Pathol. 223:307–317.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reis-Filho JS and Lakhani SR: The
diagnosis and management of pre-invasive breast disease: Genetic
alterations in pre-invasive lesions. Breast Cancer Res. 5:313–319.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dai K, Qin F, Zhang H, Liu X, Guo C, Zhang
M, Gu F, Fu L and Ma Y: Low expression of BMPRIB indicates poor
prognosis of breast cancer and is insensitive to
taxane-anthracycline chemotherapy. Oncotarget. 7:4770–4784.
2016.PubMed/NCBI
|
|
6
|
Schmitz KH, DiSipio T, Gordon LG and Hayes
SC: Adverse breast cancer treatment effects: The economic case for
making rehabilitative programs standard of care. Support Care
Cancer. 23:1807–1817. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Turchinovich A, Weiz L and Burwinkel B:
Extracellular miRNAs: The mystery of their origin and function.
Trends Biochem Sci. 37:460–465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pillai RS, Bhattacharyya SN, Artus CG,
Zoller T, Cougot N, Basyuk E, Bertrand E and Filipowicz W:
Inhibition of translational initiation by Let-7 MicroRNA in human
cells. Science. 309:1573–1576. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xiang J, Wu Y, Li DS, Wang ZY, Shen Q, Sun
TQ, Guan Q and Wang YJ: MiR-584 suppresses invasion and cell
migration of thyroid carcinoma by regulating the target oncogene
ROCK1. Oncol Res Treat. 38:436–440. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu Y, Hu J, Sun W, Li S, Deng S and Li M:
MiR-29c inhibits cell growth, invasion, and migration of pancreatic
cancer by targeting ITGB1. Onco Targets Ther. 9:99–109.
2016.PubMed/NCBI
|
|
11
|
Bai J, Zhang Z, Li X and Liu H:
MicroRNA-365 inhibits growth, invasion and metastasis of malignant
melanoma by targeting NRP1 expression. Cancer Biomark. 15:599–608.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou C, Lu Y and Li X: MiR-339-3p inhibits
proliferation and metastasis of colorectal cancer. Oncol Lett.
10:2842–2848. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dan B, Luo J, Li K and Chen S: Prognostic
value of miR-375 for survival outcomes in various cancers: A
systematic review and meta-analysis. Oncol Res Treat. 41:47–50.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin F, Yao L, Xiao J, Liu D and Ni Z:
MiR-206 functions as a tumor suppressor and directly targets K-Ras
in human oral squamous cell carcinoma. Onco Targets Ther.
7:1583–1591. 2014.PubMed/NCBI
|
|
15
|
Zheng K, Liu W, Liu Y, Jiang C and Qian Q:
MicroRNA-133a suppresses colorectal cancer cell invasion by
targeting Fascin1. Oncol Lett. 9:869–874. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang H, Yu J, Wang L, Ding D, Zhang L, Chu
C, Chen Q, Xu Z, Zou Q and Liu X: miR-320a is an independent
prognostic biomarker for invasive breast cancer. Oncol Lett.
8:1043–1050. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deng Y and Chen Y: Increased expression of
miR-29a and its prognostic significance in patients with
cholangiocarcinoma. Oncol Res Treat. 40:128–132. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu YJ, Li W, Chang F, Liu JN, Lin JX and
Chen DX: MicroRNA-505 is downregulated in human osteosarcoma and
regulates cell proliferation, migration and invasion. Oncol Rep.
39:491–500. 2018.PubMed/NCBI
|
|
19
|
Ma C, Xu B, Husaiyin S, Wang L,
Wusainahong K, Ma J, Zhu K and Niyazi M: MicroRNA-505 predicts
prognosis and acts as tumor inhibitor in cervical carcinoma with
inverse association with FZD4. Biomed Pharmacother. 92:586–594.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu L, Qiu C, Li D, Bai G, Liang J and Yang
Q: MicroRNA-505 suppresses proliferation and invasion in hepatoma
cells by directly targeting high-mobility group box 1. Life Sci.
157:12–18. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen S, Sun KX, Liu BL, Zong ZH and Zhao
Y: MicroRNA-505 functions as a tumor suppressor in endometrial
cancer by targeting TGF-alpha. Mol Cancer. 15:112016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Matamala N, Vargas MT, Gonzalez-Campora R,
Minambres R, Arias JI, Menendez P, Andres-Leon E, Gomez-Lopez G,
Yanowsky K, Calvete-Candenas J, et al: Tumor microRNA expression
profiling identifies circulating microRNAs for early breast cancer
detection. Clin Chem. 61:1098–1106. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Singletary SE, Allred C, Ashley P, Bassett
LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, et
al: Staging system for breast cancer: Revisions for the 6th edition
of the AJCC Cancer Staging Manual. Surg Clin North Am. 83:803–819.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Akram M, Iqbal M, Daniyal M and Khan AU:
Awareness and current knowledge of breast cancer. Biol Res.
50:332017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shi M and Guo N: MicroRNA expression and
its implications for the diagnosis and therapeutic strategies of
breast cancer. Cancer Treat Rev. 35:328–334. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Blank PR, Schwenkglenks M, Moch H and
Szucs TD: Human epidermal growth factor receptor 2 expression in
early breast cancer patients: A swiss cost-effectiveness analysis
of different predictive assay strategies. Breast Cancer Res Treat.
124:497–507. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Byler S, Goldgar S, Heerboth S, Leary M,
Housman G, Moulton K and Sarkar S: Genetic and epigenetic aspects
of breast cancer progression and therapy. Anticancer Res.
34:1071–1077. 2014.PubMed/NCBI
|
|
29
|
Lei F, Zhang L, Li X, Lin X, Wu S, Li F
and Liu J: Overexpression of prostate tumor overexpressed 1
correlates with tumor progression and predicts poor prognosis in
breast cancer. BMC Cancer. 14:4572014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xiong G, Deng L, Zhu J, Rychahou PG and Xu
R: Prolyl-4-hydroxylase alpha subunit 2 promotes breast cancer
progression and metastasis by regulating collagen deposition. BMC
Cancer. 14:12014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu C, He L, Zhou X, Nie X and Gu Y:
Sulfatase 2 promotes breast cancer progression through regulating
some tumor-related factors. Oncol Rep. 35:1318–1328. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dragomir M, Mafra ACP, Dias SMG, Vasilescu
C and Calin GA: Using microRNA networks to understand cancer. Int J
Mol Sci. 19:E18712018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang LL, Huang LW, Wang L, Tong BD, Wei Q
and Ding XS: Potential role of miR-139-5p in cancer diagnosis,
prognosis and therapy. Oncol Lett. 14:1215–1222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Long JP, Dong LF, Chen FF and Fan YF:
miR-146a-5p targets interleukin-1 receptor-associated kinase 1 to
inhibit the growth, migration, and invasion of breast cancer cells.
Oncol Lett. 17:1573–1580. 2019.PubMed/NCBI
|
|
35
|
Sun EH, Zhou Q, Liu KS, Wei W, Wang CM,
Liu XF, Lu C and Ma DY: Screening miRNAs related to different
subtypes of breast cancer with miRNAs microarray. Eur Rev Med
Pharmacol Sci. 18:2783–2788. 2014.PubMed/NCBI
|
|
36
|
Chai C, Wu H, Wang B, Eisenstat DD and
Leng RP: MicroRNA-498 promotes proliferation and migration by
targeting the tumor suppressor PTEN in breast cancer cells.
Carcinogenesis. 39:1185–1196. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gao S, Cao C, Dai Q, Chen J and Tu J:
miR-202 acts as a potential tumor suppressor in breast cancer.
Oncol Lett. 16:1155–1162. 2018.PubMed/NCBI
|
|
38
|
Lu X and Lu J: The significance of
detection of serum miR-423-5p and miR-484 for diagnosis of
colorectal cancer. Clin Lab. 61:187–190. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cong J, Liu R, Wang X, Wang J, Wang H and
Hou J: Low miR-498 expression levels are associated with poor
prognosis in ovarian cancer. Eur Rev Med Pharmacol Sci.
19:4762–4765. 2015.PubMed/NCBI
|
|
40
|
Li W, Jin X, Zhang Q, Zhang G, Deng X and
Ma L: Decreased expression of miR-204 is associated with poor
prognosis in patients with breast cancer. Int J Clin Exp Pathol.
7:3287–3292. 2014.PubMed/NCBI
|
|
41
|
Yu H, Li H, Qian H, Jiao X, Zhu X, Jiang
X, Dai G and Huang J: Upregulation of miR-301a correlates with poor
prognosis in triple-negative breast cancer. Med Oncol. 31:2832014.
View Article : Google Scholar : PubMed/NCBI
|
